Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
May 19, 2025 16:05 ET | Source: Humacyte, Inc

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
May 13, 2025 07:30 ET | Source: Humacyte, Inc

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter...
May 09, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
March 28, 2025 07:30 ET | Source: Humacyte, Inc

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first...
March 26, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
March 25, 2025 20:35 ET | Source: Humacyte, Inc

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
March 25, 2025 16:01 ET | Source: Humacyte, Inc

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
March 10, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – Publication of the Budget Impact...
March 03, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...